PACTG 1015: HIV-SPECIFIC CD4 AND CD8 ACTIVITY BY RECYCLING HAART IN PEDS/ADOLES

PACTG 1015：在 PEDS/ADOLES 中回收 HAART 的 HIV 特异性 CD4 和 CD8 活性

• 批准号: 7380713
• 负责人: SANDRA K BURCHETT
• 金额: $ 0.55万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7380713
• 关键词: PACTG; 1015; HIV; SPECIFIC; CD4

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary analyses evaluating potential success will consist of confidence intervals around: 1) the proportion of intermittently treated patients showing increased HIV-specific CD8 and/or CD4 activity and 2) the proportion of these patients demonstrating the ability to tolerate a drug holiday 28 days, without viral breakthrough. With continuous treatment, success rates on these endpoints would be expected to be less than 40% and 10%, respectively. Thus, findings indicating that the lower limits of 90% confidence intervals lie above the values expected with a standard, continuous HAART regimen will be taken as support for beneficial effects of intermittent treatment. The primary analyses evaluating proportions of intermittently treated patients who: 1) develop resistance, 2) have to change therapy to gain viral control after a drug holiday (with or without a change in therapy). The proportions of all such subjects will be presented along with 90% confidence intervals. Data from the continously treated group will be compared with tat from the intermittently treated group with respect to HIV-specific CD4 and CD8 activity groups, such comparisons must be interpreted with extreme caution. The primary role of the continuously treated group will be to describe the extent to which effects potentially attributable to intermittent treatment might be occurring among continuously treated patients.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。评估潜在成功的主要分析将包括置信区间：1）间歇性治疗的患者的比例显示出HIV特异性CD8和/或CD4活性增加，以及2）这些患者的比例表明能够耐受毒品假期28天的能力，而没有病毒突破。通过持续的治疗，这些终点的成功率预计将分别小于40％和10％。因此，调查结果表明，90％置信区间的下限在于标准，连续的HAART方案的预期值高于预期的值，以支持间歇性治疗的有益作用。评估间歇性治疗的患者比例的主要分析：1）：1）发展抗药性，2）必须改变治疗以在药物度假后获得病毒控制（有或没有治疗的改变）。所有此类受试者的比例将与90％的置信区间一起呈现。 相对于HIV特异性CD4和CD8活性组，将与经过间歇性治疗组的TAT进行比较，必须格外小心地解释这种比较。连续治疗组的主要作用将是描述在不断治疗的患者中可能发生潜在归因于间歇性治疗的影响程度。